Psyence BioMed Begins Phase IIb Dosing of Psilocybin Candidate NPX-5 in Australian Cancer Adjustment Disorder Trial
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Psyence Biomedical ( (PBM) ) is now available.
On April 23, 2026, Psyence BioMed announced that it has dosed the first patient in its Phase IIb trial of NPX-5, a 25 mg nature-derived psilocybin candidate, for Adjustment Disorder in cancer patients receiving palliative care. This marks the first active clinical evaluation of NPX-5 and the company’s transition to systematic human data generation across an expanded network of five Australian trial sites.
The randomized, double-blind, three-arm study is designed to assess clinical response, symptom reduction, safety, tolerability, and durability of treatment, with findings intended to shape future development and regulatory strategy for NPX-5. The program reinforces Psyence BioMed’s broader platform strategy of aligning in-house GMP production with clinical execution, potentially strengthening its position among psychedelic-focused biopharmaceutical players and signaling progress toward eventual commercialization pathways in palliative mental health care.
More about Psyence Biomedical
Psyence Biomedical Ltd., listed on Nasdaq as PBM, is a clinical-stage biopharmaceutical company focused on nature-derived psychedelic therapeutics, including psilocybin and ibogaine-based medicines. It operates a vertically integrated platform spanning GMP-compliant manufacturing, clinical development, and global supply to address unmet mental health needs across a range of disorders.
Average Trading Volume: 2,699,248
Technical Sentiment Signal: Sell
Current Market Cap: $9.7M
Learn more about PBM stock on TipRanks’ Stock Analysis page.
